Skip to main content
Top

Current Breast Cancer Reports

Issue 3/2012

Content (8 Articles)

Invited Commentary

Is HER2 Through?

George W. Sledge Jr., Lida Mina, Anna Maria Storniolo

Open Access Invited Commentary

Analysis of Cyclin D1 in Breast Cancer: A Call to Arms

Nicholas P. Tobin, Jonas Bergh

Risk, Prevention, and Screening (MC Liu, Section Editor)

Options for Surgical Prophylaxis and Reconstruction

Benjamin J. Brown, Ali Al-Attar, Scott L. Spear

Open Access Risk, Prevention, and Screening (MC Liu, Section Editor)

Comparison of Random Periareolar Fine Needle Aspirate versus Ductal Lavage for Risk Assessment and Prevention of Breast Cancer

Abigail Hoffman, Rod Pellenberg, Catherine Ibarra Drendall, Victoria Seewaldt

Risk, Prevention, and Screening (MC Liu, Section Editor)

Prophylactic Mastectomy and Risk-Reducing Salpingo-oophorectomy in BRCA1/2 Mutation Carriers

Kara N. Maxwell, Susan M. Domchek

Risk, Prevention, and Screening (MC Liu, Section Editor)

Tamoxifen versus Raloxifene versus Exemestane for Chemoprevention

Laura Reimers, Katherine D. Crew

Risk, Prevention, and Screening (MC Liu, Section Editor)

Role of Mammography versus Magnetic Resonance Imaging for Breast Cancer Screening

Linei Urban, Cícero Urban

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine